Given the cytokine nature of IL-10, an ideal delivery system should be capable of extending its half-life, improving its bioavailability, and reducing the pleiotropic effects of the cytokine, thereby enhancing its anti-inflammatory effects and clinical application potential in the treatment of pulmonary diseases. The gene discussed is IL10; the disease is lung disorder.